Trial-Results center  
Clinical trial results database 100 Feedback    Home


Related trials

BASKET-PROVE (SES), 2010 - sirolimus eluting stent vs bare-metal stent

SPIRIT IV, 2010 - everolimus eluting stent vs paclitaxel eluting stent

ISAR-DESIRE-2, 2010 - sirolimus eluting stent vs paclitaxel eluting stent

SORT-OUT-3, 2010 - zotarolimus eluting stent vs sirolimus eluting stent

GISSOC II, 2010 - sirolimus eluting stent vs bare-metal stent

RESOLUTE, 2010 - zotarolimus eluting stent vs everolimus eluting stent

BASKET-PROVE (EES), 2010 - everolimus eluting stent vs bare-metal stent

ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent

SYNTAX, 2009 - paclitaxel eluting stent vs CABG

ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent vs paclitaxel eluting stent

STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

Juwana, 2009 - sirolimus eluting stent vs paclitaxel eluting stent

DEBATER (SES vs BMS), 2009 - sirolimus eluting stent vs bare-metal stent

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent vs zotarolimus eluting stent

ZEST (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

ENDEAVOR IV, 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

BARI 2D, 2009 - CABG or PCI vs medical treatment

ZEST (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent

ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent

PASEO, 2009 - drug-eluting stents vs bare-metal stent

COMPARE, 2009 - everolimus eluting stent vs paclitaxel eluting stent

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent vs sirolimus eluting stent

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus eluting stent



See also:

  • All acute myocardial infarction clinical trials
  • All coronary artery disease clinical trials
  • All clinical trials of PCI
  • All clinical trials of sirolimus eluting stent
    		•  

    TYPHOON study, 2006

    [NCT00232830] Facebook    pdf : sirolimus eluting stent - myocardial revascularization for coronary artery disease

    Treatments

    Studied treatment Cypher or CypherSelect
    Control treatment any commerciallyavailable uncoated stent

    Patients

    Patients AMI
    Baseline characteristics
    age 59 
    diabetes (%) 16% 
    Lesion diameter inclusion criteria 2.25-3.50 
    Female (%) 22% 

    Method and design

    Randomized effectives 356 / 359 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 12 months
    Number of centre 48
    Geographic area Worldwide (15 countries)
    Primary endpoint Combination of vesselrelateddeath, AMI, TVR


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    8 / 355
         8 / 357
         classic 1,01 [0,38;2,65]

    target-vessel revascularization

    20 / 355
         47 / 357
         0,43 [0,26;0,71]

    Stent thrombosis (any, end of follow up)

    12 / 355
         13 / 357
         classic 0,93 [0,43;2,01]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 8 / 355 (2,3%) 8 / 357 (2,2%) 1,01 [0,38;2,65]    
    target-vessel revascularization 20 / 355 (5,6%) 47 / 357 (13,2%) 0,43 [0,26;0,71]    
    Stent thrombosis (any, end of follow up) 12 / 355 (3,4%) 13 / 357 (3,6%) 0,93 [0,43;2,01]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 2,25% 2,24% 0,1‰
    target-vessel revascularization 5,63% 13,17% -75,3‰
    Stent thrombosis (any, end of follow up) 3,38% 3,64% -2,6‰

    Meta-analysis of all similar trials:

    Drug eluting stent in coronary artery disease for all type of patients

    Drug eluting stent in coronary artery disease for acute myocardial infarction

    myocardial revascularization in acute myocardial infarction for all type of patients

    myocardial revascularization in coronary artery disease for all type of patient

    PCI in acute myocardial infarction for all type of patients



    Reference(s)

    Trials register # NCT00232830
    • Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C. Sirolimus-eluting versus uncoated stents in acute myocardial infarction.. N Engl J Med 2006;355:1093-104
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend